Lewy Body Dementia Market Report 2026

The lewy body dementia market size has grown strongly in recent years. It will grow from $1.2 billion in 2025 to $1.29 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to aging population growth, increased recognition of dementia subtypes, rising use of neurological examinations, expansion of hospital-based diagnosis, growing clinical focus on cognitive decline.

The lewy body dementia market size is expected to see strong growth in the next few years. It will grow to $1.69 billion in 2030 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to improving diagnostic accuracy, rising burden of chronic neurological diseases, expanding specialty clinic networks, increased caregiver and patient support programs, higher healthcare spending on dementia care. Major trends in the forecast period include rising prevalence of neurodegenerative disorders, increasing awareness and early recognition of lbd, growing demand for accurate differential diagnosis, expansion of symptom-specific drug utilization, rising need for long-term care and disease management.

The increasing prevalence of brain-related disorders is expected to drive the growth of the Lewy body dementia market in the coming years. Brain-related disorders encompass a variety of conditions that impact the brain’s structure and function, resulting in cognitive decline, memory loss, and behavioral changes. The occurrence of these disorders is rising due to factors such as aging, genetic predisposition, and environmental influences. This growing prevalence fuels the demand for improved treatments and early detection of Lewy body dementia, which in turn encourages research, funding, and innovation, leading to faster progress in diagnosis and therapy for LBD. For example, in October 2023, the World Federation of Neurology, a UK-based association of national neurological societies, reported that over 40% of the global population is affected by neurological conditions, with this burden expected to nearly double by 2050. Thus, the rising prevalence of brain-related disorders is set to propel the growth of the Lewy body dementia market.

Major companies operating in the Lewy body dementia market are prioritizing research investment to develop more effective treatments for neurodegenerative diseases. Research investment entails allocating financial resources, time, and effort to scientific and technological studies aimed at discovering new insights, creating innovative solutions, or improving existing practices. It facilitates the investigation of diseases and the development of new medications, all with the ultimate objective of enhancing patient outcomes. For example, in March 2023, the National Institute on Aging, a US-based government agency, granted $21 million to support drug development research for Lewy Body Dementia (LBD). Researchers at the University of Miami Miller School of Medicine are beginning a Phase 2b study of neflamapimod following promising early results.

In March 2023, CND Life Sciences, a US-based developer of highly precise skin-based tests to assist clinicians in diagnosing dementia with Lewy bodies, partnered with Beth Israel Deaconess Medical Center (BIDMC) to advance its skin-based diagnostic tool for neurodegenerative diseases. This collaboration seeks to utilize advanced technology to enhance the detection of misfolded alpha-synuclein proteins and investigate additional protein markers linked to other neurodegenerative disorders, ultimately enabling more accurate diagnoses and improved patient outcomes as new therapies are developed. Beth Israel Deaconess Medical Center (BIDMC) is a US-based organization specializing in diagnosing and treating conditions such as Lewy body disease.

Major companies operating in the lewy body dementia market are Eli Lilly and Company, Mayo Foundation for Medical Education and Research, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Georgetown University Medical Center, Alzheimer's Society, BioArctic AB, Annovis Bio Inc., Sun Pharma Advanced Research Company Limited, Voyager Therapeutics Inc., Cognition Therapeutics, Athira Pharma, Allergan plc, Inhibikase Therapeutics, CuraSen Therapeutics Inc., CervoMed Inc., AC Immune SA, ProMIS Neurosciences Inc., Aptinyx Inc., EIP Pharma Inc.

North America was the largest region in the lewy body dementia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the lewy body dementia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the lewy body dementia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the lewy body dementia market by increasing costs associated with imported diagnostic equipment, imaging systems, and pharmaceutical products used in disease management. These impacts are more pronounced in biomarker-based diagnosis and medication segments, particularly in regions dependent on international medical technology imports such as Asia-Pacific and parts of Europe. Hospitals and specialty clinics face procurement and operational cost pressures due to these tariffs. On the positive side, tariffs have encouraged localized manufacturing, regional sourcing, and strengthened domestic healthcare supply chains, supporting long-term market stability.

The lewy body dementia market research report is one of a series of new reports that provides lewy body dementia market statistics, including lewy body dementia industry global market size, regional shares, competitors with a lewy body dementia market share, detailed lewy body dementia market segments, market trends and opportunities, and any further data you may need to thrive in the lewy body dementia industry. This lewy body dementia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Lewy body dementia (LBD) is a progressive neurodegenerative disorder caused by abnormal protein deposits in the brain, affecting cognition, movement, and behavior. This leads to a gradual decline in both mental and physical functions, with symptoms such as memory loss, hallucinations, tremors, and motor difficulties. Proper management is crucial to address the cognitive and physical challenges associated with the condition.

The primary methods for diagnosing Lewy body dementia are clinical diagnosis and biomarker-based diagnosis. Clinical diagnosis involves detecting conditions like Lewy body dementia through medical history, symptoms, and physical examinations, facilitating early recognition and intervention. Treatment includes various medications, such as cholinesterase inhibitors, antipsychotics, antidepressants, and others, and is utilized by a range of end-users, including hospitals, specialty clinics, long-term care facilities, and more.

The lewy body dementia market consists of revenues earned by entities by providing services such as cognitive and motor function therapies, pharmaceutical treatments, and physical therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The lewy body dementia market also includes sales of sleep aids, mood stabilizers, and anxiolytics. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.